Essex Financial Services Inc. Has $748,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Essex Financial Services Inc. grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,617 shares of the medical device company’s stock after buying an additional 303 shares during the quarter. Essex Financial Services Inc.’s holdings in DexCom were worth $748,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Exchange Traded Concepts LLC increased its position in DexCom by 39.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 12,276 shares of the medical device company’s stock valued at $823,000 after acquiring an additional 3,474 shares in the last quarter. Creative Planning lifted its position in shares of DexCom by 22.3% during the third quarter. Creative Planning now owns 59,573 shares of the medical device company’s stock worth $3,994,000 after purchasing an additional 10,880 shares in the last quarter. Swedbank AB grew its stake in shares of DexCom by 15.2% during the third quarter. Swedbank AB now owns 213,864 shares of the medical device company’s stock valued at $14,337,000 after purchasing an additional 28,289 shares during the last quarter. Vontobel Holding Ltd. increased its holdings in shares of DexCom by 92.0% in the third quarter. Vontobel Holding Ltd. now owns 70,586 shares of the medical device company’s stock valued at $4,732,000 after purchasing an additional 33,820 shares in the last quarter. Finally, Orin Green Financial LLC raised its position in DexCom by 36.8% in the 3rd quarter. Orin Green Financial LLC now owns 6,540 shares of the medical device company’s stock worth $438,000 after purchasing an additional 1,759 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on DXCM. Leerink Partners decreased their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada decreased their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Raymond James dropped their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Canaccord Genuity Group raised their target price on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Oppenheimer lowered their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $98.41.

DexCom Trading Down 2.9 %

NASDAQ:DXCM opened at $83.87 on Thursday. The business’s 50-day simple moving average is $82.05 and its 200-day simple moving average is $75.13. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market capitalization of $32.76 billion, a PE ratio of 50.22, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.